vimarsana.com

Latest Breaking News On - Novel therapeutic approaches to target fgfr2 mutations in cholangiocarcinoma - Page 1 : vimarsana.com

Phase 1 Data Support Further Investigation of RLY-4008 in FGFR2+ Cholangiocarcinoma

The FGFR2 inhibitor RLY-4008 generated early evidence of efficacy in patients with cholangiocarcinoma harboring FGFR2 fusions, according to findings from the phase 1/2 ReFocus trial, which were presented at the 2023 ASCO Annual Meeting.

United statesFutibatinib lytgobiPemigatinib pemazyreErdafitinib balversaMayo clinic comprehensive cancer centerTaiho pharmaceutical coJanssen pharmaceutical companiesUpdated augustUpdated septemberUpdated aprilNovel therapeutic approaches to target fgfr2 mutations in cholangiocarcinoma

Dr Kelley on the Need for Additional Second-line Therapies in Cholangiocarcinoma

R. Kate (Katie) Kelley, MD, discusses unmet needs and treatment challenges within the current standard-of-care for patients with cholangiocarcinoma.

United statesSan franciscoR kate katie kelleyDepartment of medicineUniversity of californiaCancer immunotherapy programClinical medicineNovel therapeutic approaches to target fgfr2 mutations in cholangiocarcinomaOnclive tv

Dr Kim on the Investigation of RLY-4008 in FGFR2+ Cholangiocarcinoma

Richard Kim, MD, discusses the investigation of RLY-4008 for the treatment of patients with cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Richard kimMoffitt cancer centerGastrointestinal oncology departmentMedical gastrointestinal oncologyNovel therapeutic approaches to target fgfr2 mutations in cholangiocarcinomaOnclive tv

Dr Harding on the Rationale for Targeting FGFR2 in Cholangiocarcinoma and Biliary Tract Cancers

James Harding, MD, discusses the rationale for targeting FGFR2 in patients with cholangiocarcinoma and biliary tract cancers.

James hardingMemorial sloan kettering cancer centerNovel therapeutic approaches to target fgfr2 mutations in cholangiocarcinomaOnclive tv

vimarsana © 2020. All Rights Reserved.